paper_id,claim,figure_id,title,caption,local_image_path,url
PMC5801230,The cumulative incidence of eye complications and renal complications (Fig. 1) reduced linearly with HbA1c.,PMC5801230_figure_1,Fig. 1.,"Cumulative incidence of renal and eye complications over 50 years. Dashed lines show the cumulative incidence of ocular complications, while solid lines show the cumulative incidence of renal complications. BDR Background diabetic retinopathy, ESRD end-stage renal disease, GRP gross proteinuria, MA microalbuminuria, ME macular edema, PDR proliferative diabetic retinopathy, SVL severe vision loss",./data/PMC5801230/images/figure_1.jpg,https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e2f2/5801230/d3276b7f5804/13300_2017_344_Fig1_HTML.jpg
PMC5801230,Improvements in quality-adjusted life expectancy were much more pronounced in younger patients owing in part to the higher baseline life expectancy (Fig. 3).,PMC5801230_figure_3,Fig. 3.,Improvements in quality-adjusted life expectancy with decreasing HbA1c from 7.9% to 7.1% by baseline age,./data/PMC5801230/images/figure_3.jpg,https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e2f2/5801230/1adcb380f4b9/13300_2017_344_Fig3_HTML.jpg
PMC5801230,"Relatedly, holding HbA1c constant for 10 years, 20 years, and the full model time horizon showed diminishing improvements in quality-adjusted life expectancy (Fig. 4).",PMC5801230_figure_4,Fig. 4.,Changes in quality-adjusted life expectancy with decreasing HbA1c relative to no change in HbA1c from baseline,./data/PMC5801230/images/figure_4.jpg,https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e2f2/5801230/42499a76db99/13300_2017_344_Fig4_HTML.jpg
